Role of alpha2-adrenergic receptors and cyclic adenosine monophosphate-dependent protein kinase in the regulation of norepinephrine release in the central nervous system of spontaneously hypertensive rats.
D000316:Adrenergic alpha-Agonists / Q000493:pharmacokinetics; D000818:Animals; D000068438:Brimonidine Tartrate; D002490:Central Nervous System / Q000378:metabolism*; D003000:Clonidine / Q000008:administration & dosage / Q000493:pharmacokinetics; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D004558:Electric Stimulation; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism; D006973:Hypertension / Q000378:metabolism / Q000503:physiopathology; D007546:Isoquinolines / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D037342:Pertussis Toxin / Q000008:administration & dosage / Q000009:adverse effects; D017729:Presynaptic Terminals / Q000502:physiology; D011810:Quinoxalines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D007546:Isoquinolines; D011810:Quinoxalines; D018341:Receptors, Adrenergic, alpha-2; D000068438:Brimonidine Tartrate; C053177:N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide; D037342:Pertussis Toxin; D017868:Cyclic AMP-Dependent Protein Kinases; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D003000:Clonidine; D009638:Norepinephrine